Anti-RhD Immunoglobulin (IVIg)

About Kamada

Kamada is a vertically integrated biopharmaceutical company with a dual focus on commercial plasma-derived products and a pipeline of innovative therapeutics. Its flagship product, Glassia®, is an FDA-approved intravenous treatment for alpha-1 antitrypsin deficiency. The company leverages its manufacturing expertise to advance a pipeline of inhaled and plasma-derived therapies, while also engaging in strategic partnerships and contract development and manufacturing (CDMO) services.

Therapeutic Areas